Sellameseu, Sellaenbereo to Co-Develop Automated Cell Culture and Real-Time Functional Analysis System

Combining the CIMFS and LOCAT systems

Cellames is joining forces with Cell&Better, a company specializing in automated cell culture systems, to jointly develop an integrated system for automated cell culture and real-time functional analysis.

Cellames said on October 23 that it had signed a memorandum of understanding (MOU) with Cell&Better on October 21 for joint technology development and commercialization.

Under the agreement, the two companies will combine Cellames' MEA and impedance integrated analysis system, "CIMFS," with Cell&Better's automated culture system, "LOCAT," to develop a system that can continuously assess functional changes and drug responses in cells and organoids during long-term culture.

Cellames and Cell&Better signed a memorandum of understanding (MOU) on the 21st to jointly develop and commercialize an integrated system for automated cell culture and real-time functional analysis. Cellames

Cellames' CIMFS uses microelectrode arrays (MEA) to measure the electrical activity of cardiomyocytes and neurons, among other cells, and uses impedance analysis to noninvasively monitor changes in cell condition and function. By linking it with LOCAT, which automates culture-medium supply and exchange, perfusion, drug treatment, and sample collection, the companies aim to create an experimental environment in which cell culture and analysis can be carried out continuously.

The integrated system aims to continuously measure functional changes in cells and organoids during culture without moving them to separate analytical equipment. Biochemical analysis of automatically collected culture medium will also be incorporated, enabling comprehensive assessment of drug responses based on various indicators, including electrical activity, changes in cell condition, secretions, and metabolites.

The companies plan to expand the system's applications from functional assessments of individual heart and brain models to multi-organ assessments analyzing interactions with other organ models, such as liver and kidney models.

Cellames said, "Through this collaboration, we will expand the applications of CIMFS to automated culture and multi-organ assessment, and target the global New Approach Methodologies (NAMs) market with solutions for new drug development and efficacy and toxicity assessment that replace or complement animal testing."

This content was produced with the assistance of AI translation services.